Skip to main content
107 search results for:

Malignancy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-11-2021 | ACR 2021 | Conference coverage | Article

    ORAL Surveillance: Tofacitinib fails to show noninferiority vs TNF inhibitors for MACE, malignancy risk

    The JAK inhibitor tofacitinib is associated with numerically higher rates of MACE and malignancy than TNF inhibitors in people with rheumatoid arthritis at high cardiovascular risk, show the ORAL Surveillance results.

  2. 05-04-2019 | Teaser
    medwireNews@EULAR2018

    Expert commentary: Malignancy and infection risk with JAK inhibitors in RA patients

    EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors (5:44).  Read the accompanying news story

  3. 26-02-2018 | Malignancy | News | Article
    News in brief

    TNF inhibitor use may not increase pediatric malignancy risk

    And after adjusting for the data source, TNF inhibitor use versus no use gave a nonsignificant hazard ratio (HR) for incident malignancy of 1.58.

  4. play
    18-06-2018 | Rheumatoid arthritis | EULAR 2018 | Video

    Expert commentary: Malignancy and infection risk with JAK inhibitors in RA patients

    EULAR president Hans Bijlsma comments on a meta-analysis evaluating the risk for malignancy or serious infection among RA patients treated with JAK inhibitors (5:44). Read the accompanying news story

  5. 13-06-2018 | Rheumatoid arthritis | News | Article

    Nonsignificant increase in malignancy rates among RA patients treated with JAK inhibitors

    There was no statistically significant difference in the risk for malignancy among patients treated with JAK inhibitors alone or in combination with methotrexate versus methotrexate monotherapy, but “patients in the JAK inhibitor groups had higher rates,” said Lopez-Olivo.

  6. 08-11-2017 | Rheumatoid arthritis | ACR/ARHP 2017 | Article

    Second malignancy risk not elevated with RA biologic therapy

    The use of biologic DMARDs for rheumatoid arthritis treatment is not associated with an increased risk for a second malignancy in patients with a history of cancer, Danish study findings indicate.

  7. 15-05-2017 | Malignancy | Practical approach | Article

    Malignancy incidence, management, and prevention in patients with rheumatoid arthritis

    Wilton and Matteson discuss malignancy in patients with rheumatoid arthritis, observing that it is a major comorbidity related to both the disease and its treatment. Wilton KM, Matteson EL.  Rheumatol Ther 2017. doi:10.1007/s40744-017-0064-4

  8. 21-08-2018 | Psoriatic arthritis | Article

    Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumor-necrosis factor alpha inhibition: Results from the British Society for Rheumatology Biologics Register

    Fagerli KM et al. Rheumatology (Oxford) 2018: key241. doi: 10.1093/rheumatology/key241

  9. 01-09-2018 | DMARDs | Review | Article

    A practical approach to the use of conventional synthetic, biologic, and targeted synthetic disease modifying anti-rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy

    The authors reviewed the literature regarding the risk of malignancy in patients on conventional synthetic, biologic, and targeted synthetic DMARDS,

  10. 29-08-2016 | Comorbidities | Article

    Malignancy incidence in patients with psoriatic arthritis: a comparison cohort-based incidence study

    This retrospective population-based cohort study investigated the malignancy risk in patients with psoriatic arthritis. Wilton KM, Crowson CS, Matteson EL. Clin Rheumatol  2016;35:2603–2607. doi:10.1007/s10067-016-3396-5

  11. 13-05-2015 | Comorbidities | Article

    Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis

    This systematic literature review investigates the risk of malignancy in patients with rheumatoid arthritis and provides an update to results of a previous meta-analysis investigating this relationship. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S.  Arthritis Res Ther  2015;17:212. doi:10.1186/s13075-015-0728-9

  12. 15-12-2022 | JAK inhibitors | News | Article
    Regulatory update

    EMA restricts JAK inhibitor use in high-risk patient groups

    Click through for further details on this safety announcement

  13. 02-12-2022 | Systemic sclerosis | News | Article
    News in brief

    Anti-SSSCA1 positivity tied to cancer risk in SSc patients

    Study findings reported in Rheumatology suggest that anti-SSSCA1 antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis.

  14. 07-06-2022 | EULAR 2022 | Conference coverage | Article

    Call for CV risk assessment when starting tofacitinib in patients with PsA

    Kristensen reflected on some of the limitations of the trials, including the low numbers of MACE and malignancy events and the low total tofacitinib exposure, particularly in the PsA patients.

  15. 31-03-2022 | Rheumatoid arthritis | News | Article

    Real-world study suggests similar effectiveness of tofacitinib, TNF inhibitors

    These results follow reports from the ORAL Surveillance trial , which showed that tofacitinib is associated with higher rates of major adverse cardiovascular events and malignancy than TNF inhibitors in RA patients at high cardiovascular risk.

  16. 02-09-2021 | JAK inhibitors | News | Article
    Regulatory update

    FDA requires boxed warning updates for JAK inhibitors

    Click through for more information on this announcement

  17. 16-08-2021 | Temporal cell arteritis | Teaser

    New additions to the Adis Journal Club

    A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

  18. 08-02-2022 | Temporal cell arteritis | Teaser

    Rituximab and rheumatology practice in the COVID-19 era

    How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

  19. 20-12-2021 | Psoriatic arthritis | News | Article
    approvalsWatch

    FDA approves upadacitinib for selected psoriatic arthritis patients

    The label for upadacitinib carries a boxed warning for serious infection, mortality, MACE, malignancy, and thrombosis risk. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

  20. 20-12-2021 | Ankylosing spondylitis | News | Article
    approvalsWatch

    Tofacitinib given restricted FDA approval for ankylosing spondylitis

    Additionally, the label carries boxed warnings for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.